Shorter radiation before surgery for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a shorter course of radiation combined with two drugs (serplulimab and chemotherapy) before surgery for esophageal cancer. It aims to make tumors smaller and improve surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell carcinoma that can be removed with surgery
- You are between 18 and 75 years old
- You are generally healthy enough to get around (ECOG score 0-1)
- Your blood, liver, and kidney function meet certain minimums (we'll check with lab tests)
- You have not had other cancers recently, active autoimmune disease, or serious heart problems
- You cannot be pregnant, breastfeeding, or planning to conceive during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two immunotherapy drugs to standard chemotherapy and radiation before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a certain type of esophageal cancer that can be removed with surgery.
This trial tests a new combination of short-course radiation, an immunotherapy drug (tislelizumab), and chemotherapy before surgery for esophageal cancer. It aims to shrink tumors and improve surgical outcomes.
This trial tests if a shorter course of radiation is as effective as the standard longer course after initial chemotherapy plus immunotherapy in people with advanced esophageal cancer that cannot be surgically removed.
This study compares two standard approaches for treating esophageal cancer before surgery: chemotherapy combined with radiation versus chemotherapy combined with immunotherapy. The goal is to see which approach works better for shrinking tumors and improving outcomes in patients whose cancer is considered removable.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug called adebrelimab before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes for people with locally advanced disease.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
Hear when a new Esophageal Squamous Cell Carcinoma (ESCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.